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Abstract
Background
As of 16 May 2020, more than 4.5 million cases and more than 300,000 deaths from disease
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been
reported. Reliable estimates of mortality from SARS-CoV-2 infection are essential for under-
standing clinical prognosis, planning healthcare capacity, and epidemic forecasting. The
case–fatality ratio (CFR), calculated from total numbers of reported cases and reported
deaths, is the most commonly reported metric, but it can be a misleading measure of overall
mortality. The objectives of this study were to (1) simulate the transmission dynamics of
SARS-CoV-2 using publicly available surveillance data and (2) infer estimates of SARS-
CoV-2 mortality adjusted for biases and examine the CFR, the symptomatic case–fatality
ratio (sCFR), and the infection–fatality ratio (IFR) in different geographic locations.
Method and findings
We developed an age-stratified susceptible-exposed-infected-removed (SEIR) compart-
mental model describing the dynamics of transmission and mortality during the SARS-CoV-
2 epidemic. Our model accounts for two biases: preferential ascertainment of severe cases
and right-censoring of mortality. We fitted the transmission model to surveillance data from
Hubei Province, China, and applied the same model to six regions in Europe: Austria,
Bavaria (Germany), Baden-Württemberg (Germany), Lombardy (Italy), Spain, and Switzer-
land. In Hubei, the baseline estimates were as follows: CFR 2.4% (95% credible interval
[CrI] 2.1%–2.8%), sCFR 3.7% (3.2%–4.2%), and IFR 2.9% (2.4%–3.5%). Estimated mea-
sures of mortality changed over time. Across the six locations in Europe, estimates of CFR
varied widely. Estimates of sCFR and IFR, adjusted for bias, were more similar to each
other but still showed some degree of heterogeneity. Estimates of IFR ranged from 0.5%
(95% CrI 0.4%–0.6%) in Switzerland to 1.4% (1.1%–1.6%) in Lombardy, Italy. In all
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locations, mortality increased with age. Among individuals 80 years or older, estimates of
the IFR suggest that the proportion of all those infected with SARS-CoV-2 who will die
ranges from 20% (95% CrI 16%–26%) in Switzerland to 34% (95% CrI 28%–40%) in Spain.
A limitation of the model is that count data by date of onset are required, and these are not
available in all countries.
Conclusions
We propose a comprehensive solution to the estimation of SARS-Cov-2 mortality from sur-
veillance data during outbreaks. The CFR is not a good predictor of overall mortality from
SARS-CoV-2 and should not be used for evaluation of policy or comparison across settings.
Geographic differences in IFR suggest that a single IFR should not be applied to all settings
to estimate the total size of the SARS-CoV-2 epidemic in different countries. The sCFR and
IFR, adjusted for right-censoring and preferential ascertainment of severe cases, are mea-
sures that can be used to improve and monitor clinical and public health strategies to reduce
the deaths from SARS-CoV-2 infection.
Author summary
Why was this study done?
• Reliable estimates of measures of mortality from severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection are needed to understand clinical prognosis, to
plan healthcare capacity, and for epidemic forecasting.
• The case–fatality ratio (CFR), the number of reported deaths divided by the number of
reported cases at a specific time point, is the most commonly used metric, but it is a
biased measure of mortality from SARS-CoV-2 infection.
• The symptomatic case–fatality ratio (sCFR) and overall infection–fatality ratio (IFR) are
alternative measures of mortality with clinical and public health relevance, which should
be investigated further in different geographic locations.
What did the researchers do and find?
• We developed a mathematical model that describes infection transmission and death
during a SARS-CoV-2 epidemic. The model takes into account the delay between infec-
tion and death and preferential ascertainment of disease in people with severe symp-
toms, both of which affect the assessment of mortality.
• We applied the model to data from Hubei Province in China, which was the first place
affected by SARS-CoV-2, and to six locations in Europe—Austria, Bavaria (Germany),
Baden-Württemberg (Germany), Lombardy (Italy), Spain, and Switzerland—to esti-
mate the CFR, the sCFR, and the IFR.
• Estimates of sCFR and IFR, adjusted for bias, were similar to each other and varied less
geographically than the CFR. IFR was lowest in Switzerland (0.5%) and highest in
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Hubei Province (2.9%). The IFR increased with age; among those 80 years or older, esti-
mates ranged from 20% in Switzerland to 34% in Spain.
What do these findings mean?
• The CFR does not predict overall mortality from SARS-CoV-2 infection well and should
not be used for the evaluation of policy or for making comparisons between geographic
locations.
• There are geographic differences in the IFR of SARS-CoV-2, which could result from
differences in factors including emergency preparedness and response and health ser-
vice capacity.
• SARS-CoV-2 infection results in substantial mortality. Further studies should investi-
gate ways to reduce death from SARS-CoV-2 in older people and to understand the
causes of the differences between countries.
Introduction
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
has resulted in more than 4.5 million confirmed cases and more than 300,000 deaths from
coronavirus disease 2019 (COVID-19) as of 16 May 2020 [1]. The infection emerged in late
2019 as a cluster of cases of pneumonia of unknown origin in Wuhan, Hubei Province [2, 3].
China had reported 84,038 cases and 4,637 deaths by 16 May 2020, with no new deaths since
early April. The largest outbreaks are now in the United States of America and Western
Europe. The transmission characteristics of SARS-CoV-2 appear to be similar to those of the
1918 pandemic influenza strain [4], but at this early stage of the pandemic, the full spectrum
and distribution of disease severity and of mortality are uncertain. Reliable estimates of mea-
sures of mortality are needed to understand clinical prognosis, to plan healthcare capacity, and
for epidemic forecasting.
The case–fatality ratio (CFR), the number of reported deaths divided by the number of
reported cases at a specific time point, is the most commonly used metric because most coun-
tries collect this information [2, 5]. However, the CFR can be misleading if used to assess the
overall risk of death from an infection because of two opposing biases [6, 7]. First, because of
the delay of several weeks between symptom onset and death, the number of confirmed and
reported deaths at a certain time point does not consider the total number of deaths that will
occur among already infected individuals (right-censoring). Second, surveillance-based case
reports underestimate the total number of SARS-CoV-2–infected patients because testing
focuses on individuals with symptoms of COVID-19 and, among symptomatic cases, on
patients with more severe manifestations (preferential ascertainment). In addition, the World
Health Organization does not distinguish between SARS-CoV-2 infection and COVID-19 and
defines a confirmed case as a person with laboratory confirmation of infection irrespective of
signs and symptoms. The number of cases detected and reported therefore depends on the
extent and strategy of testing for SARS-CoV-2, especially among people without severe symp-
toms. Precisely defined measures could be more useful for describing SARS-CoV-2 mortality
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than the CFR [6]. The symptomatic case–fatality ratio (sCFR) is the proportion of infected
individuals showing symptoms who die over the course of their SARS-CoV-2 infection and is
clinically relevant to assessment of prognosis and healthcare requirements. The infection–
fatality ratio (IFR) is the proportion of all people with SARS-CoV-2 infection who will eventu-
ally die from the disease, and it is a central indicator for public health evaluation of the overall
impact of an epidemic in a given population.
Estimates of the sCFR and IFR can be obtained from prospective longitudinal studies of
representative samples of individuals with SARS-CoV-2 infection, but such studies cannot
provide the information needed for clinical and public health decision-making in real time.
The objectives of this study were to (1) simulate the dynamics of transmission and mortality of
SARS-CoV-2 using publicly available surveillance data and (2) provide overall and age-strati-
fied estimates of sCFR and IFR for SARS-CoV-2, adjusted for right-censoring and preferential
ascertainment, in different geographic locations.
Methods
We developed an age-stratified susceptible-exposed-infected-removed (SEIR) compartmental
model that describes the dynamics of SARS-CoV-2 transmission and mortality. We fitted the
model to surveillance data from Hubei Province (China) and six geographic locations in
Europe: Austria, Bavaria (Germany), Baden-Württemberg (Germany), Lombardy (Italy),
Spain, and Switzerland. There is no written prospective protocol for the study. The analysis
has been developed specifically for the research question and adapted in response to peer
review comments. Main changes include assuming pre- and asymptomatic transmissions and
running additional sensitivity analyses. In the revised version, the analysis also includes addi-
tional regions for which data had been made available. All code, including the different ver-
sions of the model and manuscript, is available from https://github.com/jriou/covid_adjusted_
cfr. This study is reported as per the TRIPOD guideline (S2 Text).
Setting and data: Hubei Province, China
The first known case of SARS-CoV-2 infection was traced back to 1 December 2019 in
Wuhan, the main city of Hubei Province, China [3]. The first reported death was on 11 Janu-
ary 2020. Human-to-human transmission of SARS-CoV-2 led to exponential growth of the
reported incidence of cases (Fig 1A). On 20 January 2020, Chinese authorities implemented
extensive control measures in Hubei: early identification and isolation of clinical cases, tracing
and quarantining of contacts, temperature checks before accessing public areas, extension of
the lunar new year holiday period, and extreme social distancing, including cancellation of
mass gatherings [8]. After 3 days, a cordon sanitaire was imposed with strict traffic restrictions.
From 27 January, the daily incidence of cases by date of symptom onset started to plateau and
then decreased.
The Chinese Center for Disease Control and Prevention (China CDC) reported the number
of cases by date of symptom onset and the age distribution of cases and deaths up to 11 Febru-
ary 2020 in China (Fig 1B) [9]. We extracted these data together with the age distribution of
the Chinese population. Death counts were obtained from a repository aggregating data from
Chinese public data sources [10]. We used data about the daily number of potentially infec-
tious contacts by age group in Shanghai [11]. We assumed that all data sources were applicable
to the population of Hubei. As of 11 February, after which information about date of symptom
onset was no longer available, there were 41,092 cases and 979 deaths, resulting in a CFR of
2.4%.
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Setting and data: Six geographic locations in Europe
The first cases of SARS-CoV-2 infection in Europe were reported at the end of January 2020.
Italy was the first country with a large epidemic after a cluster of cases, followed shortly by the
first deaths, emerged in Lombardy at the end of February. As of 16 May 2020, Europe is the
continent having reported the highest number of cases and deaths (more than 1,800,000 con-
firmed cases and 160,000 deaths) [1].
We selected European countries that reported the daily number of cases of confirmed
SARS-CoV-2 infection by date of symptoms onset. In countries in which this information was
available at a regional level, we selected worst-affected regions. We extracted data about the
number of confirmed cases by symptom onset, the daily number of deaths, and the distribu-
tion of cases and deaths across age groups for each of the six locations: Austria, Bavaria (Ger-
many), Baden-Württemberg (Germany), Lombardy (Italy), Spain, and Switzerland.
For Austria, we obtained all required data from published reports from 11 March to 14
April [12]. On 14 April, there were 14,151 reported cases and 399 deaths (CFR 2.8%). For Ger-
many, we used published data from 3 March to 16 April [13]. Age distributions, available at
the country level only, were applied to both regions. On 16 April, there were 31,196 cases (62%
with date of onset) and 802 deaths in Baden-Württemberg (CFR 2.6%) and 36,538 cases (56%
with date of onset) and 1,049 deaths in Bavaria (CFR 2.9%). For Lombardy, we collected pub-
lished data from 11 February to 25 April [14, 15]. Age distributions at the national level were
applied to Lombardy. On 25 April, there were 74,346 cases (77% with date of onset) and
Fig 1. (A) Reported number of confirmed cases of SARS-CoV-2 infection by date of symptom onset in Hubei, China, until 11 February 2020. (B) Age distribution of the
Chinese population and of the reported cases and deaths in Hubei, China. (C) Reported number of deaths associated with SARS-CoV-2 infection in Hubei, China, until 11
February 2020. (D) Age-specific contact matrix from a 2018 survey conducted in Shanghai, China [11], applied to Hubei Province. SARS-CoV-2, severe acute respiratory
syndrome coronavirus 2.
https://doi.org/10.1371/journal.pmed.1003189.g001
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13,263 deaths (CFR 17.8%). For Spain, we used published data from 2 March to 16 April [16].
On 16 April, 178,031 cases (79% with date of onset) and 19,478 deaths were reported (CFR
10.9%). For Switzerland, we used individual-level data from 2 March to 23 April aggregated by
day of onset or day of death. On 23 April, there were 33,228 cases (11% with date of onset) and
1,302 deaths (CFR 3.9%). Further details about the data are available in S1 Text, section 1.
Age-structured model of SARS-CoV-2 transmission and mortality
We used an age-stratified SEIR compartmental model that distinguished between incubating,
presymptomatic, asymptomatic, and symptomatic infections. We stratified the population
into nine 10-year groups (0–9, up to 80+ years) for all locations except Austria, for which the
age groups were 0–4, 5–14, and up to 75+ years. We assumed that susceptibility to SARS-CoV-
2 and the risk of acquisition per contact are identical for each age group and that transmission
is possible during presymptomatic and asymptomatic infections. We used age-specific contact
matrices to model contact patterns according to age group (contact matrix derived by Zhang
and colleagues for Hubei [11] and the POLYMOD contact matrix for the six European loca-
tions [17]). We modeled the decrease in SARS-CoV-2 transmission due to control measures
using a logistic function for the transmission rate.
In the model, after an average incubation period of 5.0 days [18], 81% (95% credible interval
[CrI] 71%–89%) of infected people develop symptoms of any severity, and the rest remain
asymptomatic [19, 20]. The estimated proportion of symptomatic infections was derived from
outbreak investigations included in a systematic review and is implemented as a beta distribu-
tion to propagate uncertainty. Studies that have estimated the proportion of asymptomatics
have not provided conclusive evidence of an age trend, so we assumed it to be constant [21].
We assumed reduced infectiousness during the period of 2.3 days preceding symptom onset
(presymptomatic compartment) and also among asymptomatic individuals [18].
The model was used to compute the number of symptomatic SARS-CoV-2 infections by
day of symptom onset in each age group. We applied an age-specific ascertainment proportion
to the number of symptomatic infections to estimate the number of reported cases of SARS-
CoV-2 infections by date of symptom onset. To identify the parameters, we assumed that
100% of infections in the oldest age group (80+ years old, 75+ years old in Austria) were
reported. We assumed that mortality only occurred in symptomatic people and that the time
from symptom onset to death followed a log-normal distribution with mean 20.2 days and
standard deviation 11.6 [22]. This allowed us to account for the deaths occurring after the date
of data collection.
Separately for Hubei and the six European locations, we simultaneously fitted our model to
the data sets described above (Fig 1): (1) the number of confirmed cases by day of symptom
onset, (2) the number of deaths by day of occurrence, (3) the age distribution of all confirmed
cases, and (4) the age distribution of all reported deaths. We assumed a negative binomial dis-
tribution for data sets 1 and 2 and a multinomial distribution for data sets 3 and 4. All parame-
ters were estimated from data except for the incubation period, the generation time, the
contribution of presymptomatics to transmission, the presymptomatic duration, and the time
from symptom onset to death.
The fitted model was used to produce estimates (median posterior distributions with 95%
CrIs) of the total number of symptomatic and presymptomatic/asymptomatic infections
(adjusted for preferential ascertainment) and of the total number of deaths (adjusted for right-
censoring). These were then transformed into adjusted estimates of sCFR and IFR. Besides
parameter values and model structure, these estimates rely on the following additional
assumptions:
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• The severity of symptoms differs by age group and influences the probability of reporting.
• All deaths due to SARS-CoV-2 infection have been identified and reported.
• The susceptibility to SARS-CoV-2 infection is identical across age groups.
• The average standard of care is stable for the period of interest and the next 2 months, during
which a proportion of the infected people will eventually die.
• The ascertainment probability by age is constant over the periods considered.
Further details about the method are available in S1 Text, section 2.
Sensitivity analysis
From 12 February 2020, the Chinese authorities changed their criteria for reporting cases,
increasing the total by more than 25,000. Reported numbers of deaths increased on 16 April,
when Wuhan city reported an additional 1,290 deaths. We ran a sensitivity analysis with cor-
rected numbers of cases and deaths in Hubei Province. We also examined the impact of
assuming a 50% lower susceptibility in individuals 0–19 years old and of a lower ascertainment
among those 80 years or older (from 90% to 10%, compared with a fixed proportion of 100%
in the main analysis). We also refitted the model at different dates of data collection (every 5
days from 12 January to 11 February) to examine the effect of the accumulation of data over
time. Additional sensitivity analyses are presented in S1 Text, section 6.
We implemented the model in a Bayesian framework using Stan [23]. All code and data are
available from https://github.com/jriou/covid_adjusted_cfr.
Results
Our model accurately describes the dynamics of transmission and mortality by age group dur-
ing the SARS-CoV-2 epidemic in Hubei from 1 January to 11 February 2020 (Fig 2). The
model predicts that control measures implemented from 20 January reduced SARS-CoV-2
transmissibility by 92% (95% CrI 87%–100%), with a steep diminution in case incidence 4.3
(95% CrI 3.2–5.4) days after 20 January. Assuming 100% of cases aged 80 and older were ini-
tially reported, we estimate that a total of 83,300 individuals (95% CrI 73,000–98,600) were
infected in Hubei between 1 January and 11 February 2020. Of these, the number of symptom-
atic cases is estimated at 67,000 (95% CrI 60,500–73,600), 1.6 times (95% CrI 1.5–1.8) more
than the 41,092 reported cases during that period. Accounting for the later correction in the
number of reported cases, the total number of infections increases to 138,000 (95% CrI
120,000–162,000). The proportion of ascertained cases by age group increased from less than
9% (95% CrI 8%–10%) under 20 years old to 93% (95% CrI 88%–98%) in the age group 70–79
(the ascertainment proportion was assumed to be 100% in the age group 80+, Fig 3A).
The model predicts a total of 2,450 deaths (95% CrI 2,230–2,700) among all people infected
until 11 February in Hubei (compared with 979 deaths at this point without adjusting for
right-censoring). This results in an estimated IFR of 2.9% (95% CrI 2.4%–3.5%, Table 1).
Assuming the later correction of deaths was evenly distributed by date of symptom onset and
age group, the total number of deaths increases to 3,430 (95% CrI 3,120–3,760). When using
the corrected numbers of cases and deaths, we derived an IFR of 2.5% (95% CrI 2.1%–2.9%).
The estimated sCFR, which is more relevant to the clinical setting, was 3.7% (95% CrI
3.2%–4.2%) in the baseline analysis and 3.1% (95% CrI 2.7%–3.6%) after correction of the
increased number of reported cases and deaths. The estimated sCFR increased with age (S1
Text, section 5): under 20 years of age, below 1 in 1,000; 20–49 years, between 3 and 8 per
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1,000; 50–59 years, 2.5% (95% CrI 2.0%–3.0%); 60–69 years, 8.0% (95% CrI 6.9%–9.3%); 70–
79 years, 19.3% (95% CrI 16.7%–22.1%); 80 years and older, 39.0% (95% CrI 33.1%–46.1%).
In sensitivity analyses, the correction of the number of reported cases (+65%) and deaths
(+40%) by the local authorities in Hubei did not influence the ascertainment proportion (Fig
3A) but led to a proportional decrease of the sCFR and IFR estimates by 15%, which was
expected from the correction applied (1.40/1.65 = 0.85, Fig 3B and Table 1). Second, lowering
the susceptibility of individuals aged 0–19 years by 50% did not affect the ascertainment pro-
portion or the sCFR in other age groups (Fig 3A and 3B). The decrease in the denominator led
to a proportional increase of total sCFR and IFR. Third, relaxing the assumption of complete
reporting of cases among individuals aged 80 years and older resulted in a proportional
decrease of the sCFR and IFR (Fig 3C). Fourth, patterns in the observed mortality changed as
the epidemic progressed (Fig 3D). The CFR increased as delayed deaths were reported. The
sensitivity analysis suggests that our proposed approach overestimates the sCFR and IFR when
applied before the peak of incidence (around 27 January) and stabilizes afterward. Additional
sensitivity analyses examining how the contribution of presymptomatic transmission, the sus-
ceptibility of children, and several other choices in model structure and parameter values were
conducted and did not impact the results (S1 Text, section 6).
Fig 2. Model fit for Hubei, China, of (A) incident cases of SARS-CoV-2 infection by date of symptom onset, (B) total cases, (C) age distribution of cases, (D) incidence of
deaths, (E) total number of deaths among individuals infected until 11 February 2020, and (F) age distribution of deaths. White circles and bars represent data. Lines and
shaded areas or points and ranges show the posterior median and 95% credible intervals for six types of model output: reported cases, symptomatic cases, overall cases (i.e.,
symptomatic and asymptomatic cases), reported deaths until 11 February 2020, projected deaths after 11 February 2020, and overall deaths. SARS-CoV-2, severe acute
respiratory syndrome coronavirus 2.
https://doi.org/10.1371/journal.pmed.1003189.g002
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We applied the same model to data from six European locations with all required data: Aus-
tria, Germany (Baden-Württemberg and Bavaria), Italy (Lombardy), Spain, and Switzerland.
The model fit was satisfactory in all cases (S1 Text, section 3). CFR estimates differed widely
between countries, whereas sCFR and IFR estimates were more similar to each other (Table 1
and Fig 4A). Across countries, model estimates of IFR ranged from 0.5% (95% CrI 0.4%–0.6%)
in Switzerland to 1.4% (95% CrI 1.1%–1.6%) in Lombardy, Italy. The patterns of age-specific
IFR estimates were similar across locations (Fig 4B), despite differences in the surveillance-
reported age distribution of cases (Fig 4C). Some degree of variability remained between age-
specific IFR estimates, especially in older age groups. Compared with Hubei Province, higher
proportions of cases in European locations were in older age groups, suggesting higher levels
of preferential ascertainment of severe cases. This appears in the estimated patterns of the age-
specific ascertainment proportion, with a generally lower ascertainment of age groups 20–79
Fig 3. (A) Estimated proportion of cases ascertained by age group in Hubei, China (baseline, after the later correction of the number of reported cases and deaths, and
assuming 50% lower susceptibility of children aged 0–19). (B) Estimated case symptomatic fatality ratio by age group in Hubei, China. (C) Impact of varying the fixed
proportion of cases ascertained among individuals aged 80 and older from 10% to 100% on the mortality estimates. (D) Mortality estimates at different dates of reporting
(every 5 days from January 12 to February 11). CFR, case–fatality ratio; IFR, infection–fatality ratio; sCFR, symptomatic case–fatality ratio.
https://doi.org/10.1371/journal.pmed.1003189.g003
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in Europe compared with Hubei (Fig 4D). Additional results are presented in S1 Text,
section 5.
Discussion
In this modeling study, we estimate different measures of mortality from SARS-CoV-2 infec-
tion in Hubei Province, China, and six geographic locations in Europe. After adjusting for
right-censoring and preferential ascertainment, we estimate the IFR in Hubei to be 2.9%
(2.4%–3.5%), which is higher than the CFR of 2.4%. In different European settings, estimates
of IFR ranged from 0.5% (95% CrI 0.4%–0.6%) in Switzerland to 1.4% (95% CrI 1.1%–1.6%)
in Lombardy, compared with CFRs of 3.9% and 17.8%, respectively. The model estimates of
mortality show a strong age trend in all locations, with very high risks in people aged 80 years
and older: between 20% (95% CrI 16%–26%) in Switzerland and 34% (95% CrI 28%–40%) in
Lombardy.
Strengths and limitations
Our work has four important strengths. First, we distinguish between the crude CFR and two
separate measures of mortality, sCFR and IFR. Second, we use a mechanistic model for the
transmission of SARS-CoV-2 and the mortality associated with SARS-CoV-2 infection which
directly translates the data-generating mechanisms that lead to biased observations of the
number of deaths (because of right-censoring) and of cases (because of preferential ascertain-
ment). Our model also accounts for the effect of control measures on disease transmission. We
implemented the model in a Bayesian framework in order to propagate most sources of uncer-
tainty from data and parameter values into the estimates. In Hubei, because the model cap-
tured most of the epidemic first wave, the predicted number and timing of deaths could be
Table 1. Model estimates of total infections of SARS-CoV-2 infection, attack rate, total deaths, CFR, sCFR, and IFR by location until the limit date.
Location (limit date) Estimated total infections Estimated attack
rate
Estimated total
deaths
CFR sCFR IFR
Hubei, China (11 February)
Baseline 83,300 (73,000–98,600) 0.1% (0.1%–0.2%) 2,450 (2,230–2,700) 2.4% 3.7% (3.2%–
4.2%)
2.9% (2.4%–
3.5%)
After correction 138,000 (120,000–162,000) 0.2% (0.2%–0.3%) 3,430 (3,120–3,760) 2.0% 3.1% (2.7%–
3.5%)
2.5% (2.1%–
2.9%)
With lower susceptibility of children 74,100 (63,600–86,700) 0.1% (0.1%–0.1%) 2,440 (2,230–2,710) 2.4% 4.1% (3.6%–
4.7%)
3.3% (2.7%–
4.0%)
Austria (14 April) 69,100 (56,500–82,700) 0.8% (0.6%–0.9%) 731 (623–867) 2.8% 1.3% (1.1%–
1.6%)
1.1% (0.8%–
1.3%)
Baden-Württemberg, Germany (16
April)
212,000 (188,000–247,000) 1.9% (1.7%–2.2%) 1,580 (1,060–2,710) 2.6% 0.9% (0.6%–
1.6%)
0.7% (0.5%–
1.3%)
Bavaria, Germany (16 April) 257,000 (228,000–296,000) 2.0% (1.7%–2.3%) 1,940 (1,420–2,720) 2.9% 0.9% (0.7%–
1.3%)
0.8% (0.5%–
1.1%)
Lombardy, Italy (25 April) 1,150,000 (1,010,000–
1,350,000)
11.5% (10.1%–
13.4%)
15,700 (13,900–
17,600)
17.8% 1.7% (1.5%–
2.0%)
1.4% (1.1%–
1.6%)
Spain (16 April) 2,650,000 (2,360,000–
3,090,000)
5.7% (5.0%–6.6%) 27,800 (25,400–
30,500)
10.9% 1.3% (1.2%–
1.5%)
1.0% (0.9%–
1.2%)
Switzerland (23 April) 308,000 (248,000–383,000) 3.6% (2.9%–4.5%) 1,520 (1,380–1,690) 3.9% 0.6% (0.5%–
0.8%)
0.5% (0.4%–
0.6%)
Abbreviations: CFR, case–fatality ratio; IFR, infection–fatality ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; sCFR, symptomatic case–fatality
ratio
https://doi.org/10.1371/journal.pmed.1003189.t001
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compared with later reports of SARS-CoV-2 deaths, providing some degree of external valida-
tion (S1 Text, section 4). Third, our model is stratified by age group, which has been shown as
a crucial feature for modeling emerging respiratory infections [24]. Fourth, the model uses sur-
veillance data that can be collected routinely, and it does not require individual-level data or
studies in the general population.
Our study has several limitations. First, an important assumption is that all cases in symp-
tomatic individuals aged 80 years and older were reported as a result of the more severe symp-
toms at older ages. We cannot confirm this, but the high risk of death from SARS-CoV-2
infection among the elderly was reported very early on [3], so we believe that most old people
with symptoms sought care. Sensitivity analyses show that sCFR and IFR estimates decrease
linearly, with a lower ascertainment of infections among individuals aged 80 years and older
(Fig 3C). For the IFR in Hubei Province to be below 0.5%, fewer than 15% of infections in indi-
viduals aged 80 years and older would have been ascertained by the local authorities.
Fig 4. (A) CFR, sCFR, and IFR estimates by geographic location. (B) IFR estimates by age group and location (for Austria, the estimates are adapted to the available age
groups from 0–4 to 75+ years). (C) Proportion of cases ascertained by age group and location (color code as for panel B). (D) Distribution of reported cases by age group
by location (color code as for panel B). CFR, case–fatality ratio; C, China; G, Germany; I, Italy; IFR, infection–fatality ratio; sCFR, symptomatic case–fatality ratio.
https://doi.org/10.1371/journal.pmed.1003189.g004
PLOS MEDICINE SARS-CoV-2 mortality during the early stages of an epidemic
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003189 July 28, 2020 11 / 17
Second, our model requires surveillance data about the incidence of cases of reported
SARS-CoV-2 by date of symptom onset. When information on symptom onset is only avail-
able for a subset of cases, we have to assume that data are missing at random. Additionally,
within a given geographic location, the model assumes a constant ascertainment proportion
and a constant mortality for each age group during the period. When repeating the analysis at
different stages of the epidemic in Hubei, we found that estimates obtained before the epi-
demic peak led to overestimation of the sCFR and IFR (Fig 3D). This finding could be the
result of a decrease in mortality as the epidemic progresses, but it could also be attributed to a
lower ability of the model to estimate the epidemic size before epidemic peak is reached, a
common problem in epidemic modeling [25].
Third, we assume that the deficit of reported cases among younger age groups is a result of
preferential ascertainment, whereby younger individuals have milder symptoms and are less
likely to seek care, and does not reflect a lower risk of infection in younger individuals. During
the pandemic of H1N1 influenza, lower circulation in older individuals was attributed to resid-
ual immunity [26]. There is no indication of preexisting immunity to SARS-CoV-2 in humans
[8]. Lower susceptibility of only younger individuals for immunological reasons seems
unlikely. Different contact patterns could contribute to different attack rates by age group. We
include age-specific contact patterns in the model, so our results are dependent on the contact
matrix used. In a sensitivity analysis with 50% reduced susceptibility in children, the estimates
of age-specific IFR in other age groups did not change, but the lower number of total infections
led to a higher IFR.
Fourth, the proportion of SARS-CoV-2 infections that remains asymptomatic is still uncer-
tain. To propagate this uncertainty into the results, we implemented a prior distribution
informed by the findings of outbreak investigations included in a living systematic review and
meta-analysis [19, 20]. Our estimate is in agreement with the findings of a statistical modeling
study of an outbreak on the cruise ship Diamond Princess, estimating an average proportion of
symptomatic infections of 82.1% (95% CrI 79.8%–84.5%) [27]. Another study of 87 contacts of
infected cases in Shenzhen, China, estimated that 80.4% (95% CrI 70.9%–87.4%) were symp-
tomatic [18]. Additionally, dichotomization into asymptomatic and symptomatic is a simplifi-
cation; SARS-CoV-2 causes a spectrum of symptoms that likely depend on age, sex, and
comorbidities. Serological surveys in the general population will be needed to better character-
ize asymptomatic infections [28].
Comparison with other studies
Our model-based estimates have some degree of external validation from serological studies of
previous exposure to SARS-CoV-2. In Geneva, Switzerland, a study reported an attack rate of
9.7% (95% confidence interval 6.1%–13.1%) in the city, resulting in an IFR of 0.6%, which is
very close to our national estimate for Switzerland [29]. Preliminary results from a national
seroprevalence study in Spain with more than 60,000 participants found an attack rate of 5.0%
(95% confidence interval 4.7%–5.4%), consistent with our estimate of 5.7% (95% CrI 5.0%–
6.6%) [30]. A study of excess mortality in Italy estimated 17,786 ± 269 deaths in Lombardy,
which is close to our credibility interval for the number of total deaths [31]. This study did not
attempt to estimate the size of the epidemic but only applied the proportion of positive tests to
the population to obtain an upper limit of epidemic size, which resulted in a lower bound for
the IFR of 0.6% in Lombardy.
Model-based estimates of mortality from SARS-CoV-2 in China, adjusting for bias, vary.
Our estimate for Hubei Province is higher than the sCFR of 1.4% estimated in two other
modeling studies [32, 33]. Differences in modeling approaches and assumptions explain the
PLOS MEDICINE SARS-CoV-2 mortality during the early stages of an epidemic
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003189 July 28, 2020 12 / 17
variation. Verity and colleagues used a similar modeling approach but applied their findings to
all of mainland China, where mortality outside Hubei Province appeared lower [9]. This paper
also assumed a homogeneous attack rate across age groups rather than simulating epidemics
using an age-specific contact matrix. Wu and colleagues used another approach, assuming that
susceptibility to infection varies by age. Both Verity and colleagues and Wu and colleagues
used data from individuals leaving Wuhan before lockdown was implemented to infer ascer-
tainment, while we fixed it to 100% for the oldest age group. This resulted in comparatively
lower ascertainment proportions (up to 70% for the oldest age groups in Verity and colleagues,
2% for Wu and colleagues) and consequently to higher estimates of epidemic size and lower
estimates of sCFR. The use of data from travelers might result in bias, especially if people who
can travel are healthier than the general population.
Other studies that attempt to adjust for right-censoring of deaths give different estimates of
mortality in China than in our study. A study using a competing risk model estimated mortal-
ity at 7.2% (95% confidence interval 6.6%–8.0%) for Hubei Province [34]. Using data on
exported cases, another team estimated mortality of 5.3% (95% confidence interval 3.5%–
7.5%) among confirmed cases in China [35]. Another team reported a CFR of 18% (95% CrI
11%–81%) among cases detected in Hubei, accounting for the delay in mortality, and esti-
mated the IFR at 1.0% (95% CI 0.5%–4%), based on data from the early epidemic in Hubei
and from cases reported outside China [36]. Our estimate of mortality among all infected cases
in Hubei is also higher than in an earlier version of this work (2.9% against 1.6%) [37]. We
believe the newer estimate to be more reliable for two reasons. First, we implemented age-spe-
cific risks of transmission through a contact matrix, which partially explains the age patterns
in reported SARS-CoV-2 infections and leads to lower estimates of the total number of infec-
tions, thus increasing mortality. Second, a higher estimated proportion of symptomatic people
based on new data also led to higher estimates of mortality among all infected.
Interpretation and implications
In this study, we propose a comprehensive solution to the estimation of mortality from surveil-
lance data during outbreaks using two measures of mortality [6]. Adjusted for right-censoring
and preferential ascertainment of severe cases, the IFR is a measure of overall mortality associ-
ated with SARS-CoV-2 infection that can be used to assess the potential consequences of the
pandemic, e.g., using theoretical estimates of final epidemic size [38]. The sCFR is a measure
of mortality that is most relevant to the clinical setting for assessment of prognosis and prioriti-
zation of healthcare services. Crude CFR estimates are a poor predictor of mortality from
SARS-CoV-2 infection, as demonstrated for instance by the comparison of CFR and IFR val-
ues in Switzerland (high CFR, lowest IFR) and Hubei (lowest CFR, highest IFR). In addition to
the inherent biases, the wide variation in CFR between geographic locations is likely to reflect
external factors, including policies for testing and differences in systems of surveillance and
reporting more than differences in mortality. Crude CFR values should therefore not be used
for evaluating policy or making comparisons across settings.
Our model-based estimates of the IFR and sCFR varied geographically (Fig 4A). The high-
est estimate of IFR was found in Hubei Province (2.9%; 95% CrI 2.4%–3.5% in the baseline
analysis). The steep increase in mortality among people aged 60 years and older, reaching very
high values in people aged 80 years and older, is of concern. The credibility of this estimate
and of our approach for adjusting for right-censoring is supported by the model predictions of
reported daily SARS-CoV-2–associated deaths in Hubei Province after 11 February (S1 Text,
section 4). The estimated IFR decreases to 2.5% (95% CrI 2.1%–2.9%) when accounting for the
later correction of reported cases and deaths by the local authorities and increases to 3.3%
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(95% CrI 2.7%–4.0%) if we consider a lower susceptibility of individuals under 20 years. We
also show that applying our model at earlier stages of the epidemic would have resulted in
higher estimates of sCFR and IFR and more uncertainty (Fig 3D). However, our estimates
here correspond to an average value over the considered period, and it has been shown that
mortality has changed over time as a result of an improvement of the standard of care [8].
The estimated IFR in Lombardy, 1.4% (95% CrI 1.1%–1.6%), was lower than in Hubei
Province but higher than in five other European locations. Further research is necessary to bet-
ter understand the factors associated with SARS-CoV-2 mortality. These differences highlight
the importance of local factors on the outcome of SARS-CoV-2 infection, including demo-
graphic characteristics. A partial explanation for the remaining heterogeneity is the lower
degree of preparedness and health service capacity in northern Italy, which in Europe was
affected first by the SARS-CoV-2 epidemic. Consequently, we suggest that a single mortality
estimate should not be applied to all settings to estimate the total size of the epidemic [39].
This study shows that the IFR and sCFR, adjusted for right-censoring and preferential ascer-
tainment biases, are appropriate measures of mortality for SARS-CoV-2 infection and can be
used to improve and monitor clinical and public health strategies to reduce the deaths from
SARS-CoV-2 infection.
Conclusions
We developed a mechanistic approach to correct the CFR for bias due to right-censoring and
preferential ascertainment and provide adjusted estimates of mortality due to SARS-CoV-2
infection by age group. We applied this approach to seven different settings, showing that
widely different estimates for the CFR corresponded in fact to more similar estimates of the
IFR, around 3% in Hubei Province, China, and ranging between 0.5% and 1.4% in six included
European locations. Despite these similarities, substantial heterogeneity remains in the IFR
estimates across settings, indicating the impact of local conditions on the outcome of SARS-
CoV-2 infection. The steep increase in mortality among people aged 60 years and older, reach-
ing very high values in people aged 80 years and older, is of concern.
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